Neoadjuvant therapy for melanoma: past, present, and future.
Surg Oncol
; 56: 102127, 2024 Oct.
Article
en En
| MEDLINE
| ID: mdl-39236515
ABSTRACT
Modern systemic therapy has dramatically improved outcomes for many patients with advanced metastatic melanoma. The success of these therapies has attracted much scientific interest while these therapies have made their way into the treatment of earlier stages of disease. Randomized trials have led to the approval of adjuvant immunotherapy and targeted therapy for resected stage III melanoma. However, most recently, these therapies have gained traction in the neoadjuvant setting. Promising early results led to randomized controlled trials that have now established neoadjuvant therapy as standard of care in advanced melanoma patients. Questions remain regarding the optimal choice of therapy, duration and timing of neoadjuvant therapy, extent of surgery, and the need for additional adjuvant therapy for patients who received neoadjuvant therapy. Herein we provide an overview of neoadjuvant therapy for melanoma and dilemmas to its broader applications.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Terapia Neoadyuvante
/
Melanoma
Límite:
Humans
Idioma:
En
Revista:
Surg Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos